Impairment of digoxin clearance by coadministration of quinidine
- PMID: 7309901
- DOI: 10.1002/j.1552-4604.1981.tb01739.x
Impairment of digoxin clearance by coadministration of quinidine
Abstract
Seven healthy volunteers received a single 1.0-mg dose of intravenous digoxin in a drug-free control trial and again during concurrent therapy with therapeutic doses of quinidine. Digoxin kinetics were determined from multiple serum digoxin concentrations measured during 72 hours after dosage. Compared to the control state, quinidine coadministration reduced mean digoxin volume of distribution (15.1 vs. 12.4 l./kg), prolonged its elimination half-life (47.7 vs. 75.7 hours), and significantly reduced total clearance (6.06 vs. 2.18 ml/min.kg). Both renal and extrarenal digoxin clearances were impaired by quinidine. In nine cardiac patients receiving long-term digoxin therapy (0.25 mg twice daily), quinidine coadministration elevated mean morning digoxin levels from 1.37 to 2.0 ng/ml (P less than 0.001) and evening levels from 1.44 to 1.97 ng/ml (N.S.). If digoxin concentrations at the site of action are increased by quinidine, the interaction is likely to be of clinical importance in many patients.
Similar articles
-
Digoxin-quinidine interaction Pharmacokinetic evaluation.N Engl J Med. 1979 May 31;300(22):1238-41. doi: 10.1056/NEJM197905313002202. N Engl J Med. 1979. PMID: 431681
-
Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?Int J Clin Pharmacol Ther Toxicol. 1985 Mar;23(3):145-53. Int J Clin Pharmacol Ther Toxicol. 1985. PMID: 3997300 Clinical Trial.
-
Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration.Acta Pharmacol Toxicol (Copenh). 1983 May;52(5):357-63. doi: 10.1111/j.1600-0773.1983.tb01115.x. Acta Pharmacol Toxicol (Copenh). 1983. PMID: 6880771
-
Quinidine and digoxin. An important interaction.Drugs. 1982 Sep;24(3):229-39. doi: 10.2165/00003495-198224030-00003. Drugs. 1982. PMID: 6751790 Review.
-
Current status of cardiac glycoside drug interactions.Clin Pharm. 1985 Jul-Aug;4(4):404-13. Clin Pharm. 1985. PMID: 2412751 Review.
Cited by
-
Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.Clin Pharmacol Ther. 2022 Sep;112(3):573-592. doi: 10.1002/cpt.2670. Epub 2022 Jun 22. Clin Pharmacol Ther. 2022. PMID: 35612761 Free PMC article. Review.
-
Renal drug transporters and their significance in drug-drug interactions.Acta Pharm Sin B. 2016 Sep;6(5):363-373. doi: 10.1016/j.apsb.2016.07.013. Epub 2016 Aug 9. Acta Pharm Sin B. 2016. PMID: 27709005 Free PMC article. Review.
-
Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology.Cardiovasc Drugs Ther. 1987 Aug;1(2):183-9. doi: 10.1007/BF02125472. Cardiovasc Drugs Ther. 1987. PMID: 3154322 Review.
-
Clinical chemistry of anti-arrhythmic drugs.Indian J Clin Biochem. 1999 Jan;14(1):95-9. doi: 10.1007/BF02869154. Indian J Clin Biochem. 1999. PMID: 23105205 Free PMC article. No abstract available.
-
Performance and Sensitivity of [99mTc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver.Mol Pharm. 2024 Feb 5;21(2):932-943. doi: 10.1021/acs.molpharmaceut.3c01036. Epub 2024 Jan 15. Mol Pharm. 2024. PMID: 38225758 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous